Last reviewed · How we verify
Clobetasone Butyrate 0.05% Cream
Clobetasone Butyrate 0.05% Cream is a Topical corticosteroid Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis).
Clobetasone butyrate is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Clobetasone butyrate is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis).
At a glance
| Generic name | Clobetasone Butyrate 0.05% Cream |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Clobetasone butyrate is a Class III (mild-to-moderate potency) topical corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced immune cell infiltration. This results in reduced erythema, pruritus, and other signs of skin inflammation. The 0.05% cream formulation is designed for topical application to affected skin areas.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
- Folliculitis
Key clinical trials
- Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) (PHASE3)
- Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety (PHASE3)
- Evaluation of Anti-inflammatories in the Reduction of Bite Reactions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clobetasone Butyrate 0.05% Cream CI brief — competitive landscape report
- Clobetasone Butyrate 0.05% Cream updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Clobetasone Butyrate 0.05% Cream
What is Clobetasone Butyrate 0.05% Cream?
How does Clobetasone Butyrate 0.05% Cream work?
What is Clobetasone Butyrate 0.05% Cream used for?
Who makes Clobetasone Butyrate 0.05% Cream?
What drug class is Clobetasone Butyrate 0.05% Cream in?
What development phase is Clobetasone Butyrate 0.05% Cream in?
What are the side effects of Clobetasone Butyrate 0.05% Cream?
What does Clobetasone Butyrate 0.05% Cream target?
Related
- Drug class: All Topical corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)
- Compare: Clobetasone Butyrate 0.05% Cream vs similar drugs
- Pricing: Clobetasone Butyrate 0.05% Cream cost, discount & access